Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRE NASDAQ:NLTX NASDAQ:NRIX NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$8.17+6.5%$7.61$6.11▼$19.00$786.85M1.86160,200 shs129,718 shsNLTXNeoleukin Therapeutics$19.25-1.0%$20.76$2.03▼$14.36$180.91M1.1150,104 shs55,926 shsNRIXNurix Therapeutics$8.95-2.7%$10.87$8.18▼$29.56$684.22M2.1862,110 shs713,377 shsTNGXTango Therapeutics$6.36-6.7%$6.56$1.03▼$10.85$707.61M1.641.73 million shs1.36 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-2.79%-0.52%+6.68%-9.12%-38.69%NLTXNeoleukin Therapeutics-2.51%+5.25%-8.34%-9.87%-44.43%NRIXNurix Therapeutics-5.15%+0.99%-6.50%-27.16%-60.75%TNGXTango Therapeutics+0.15%+2.40%+3.18%+43.88%-25.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$8.17+6.5%$7.61$6.11▼$19.00$786.85M1.86160,200 shs129,718 shsNLTXNeoleukin Therapeutics$19.25-1.0%$20.76$2.03▼$14.36$180.91M1.1150,104 shs55,926 shsNRIXNurix Therapeutics$8.95-2.7%$10.87$8.18▼$29.56$684.22M2.1862,110 shs713,377 shsTNGXTango Therapeutics$6.36-6.7%$6.56$1.03▼$10.85$707.61M1.641.73 million shs1.36 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-2.79%-0.52%+6.68%-9.12%-38.69%NLTXNeoleukin Therapeutics-2.51%+5.25%-8.34%-9.87%-44.43%NRIXNurix Therapeutics-5.15%+0.99%-6.50%-27.16%-60.75%TNGXTango Therapeutics+0.15%+2.40%+3.18%+43.88%-25.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 3.00Buy$18.00120.32% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ANRIXNurix Therapeutics 2.88Moderate Buy$29.07224.82% UpsideTNGXTango Therapeutics 3.00Buy$10.5065.09% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, GYRE, TNGX, and NRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025GYREGyre TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/18/2025TNGXTango TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.008/6/2025TNGXTango TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.007/31/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $30.007/15/2025NRIXNurix TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$17.00 ➝ $16.007/14/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $34.007/10/2025NRIXNurix TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $26.007/10/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $30.007/10/2025NRIXNurix TherapeuticsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$105.76M7.44$0.20 per share39.95$1.05 per share7.78NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ANRIXNurix Therapeutics$88.38M7.74N/AN/A$7.44 per share1.20TNGXTango Therapeutics$42.07M16.82N/AN/A$1.86 per share3.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics$12.09M$0.01817.82∞N/A4.08%7.67%6.19%11/12/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ANRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.33N/AN/AN/A-599.11%-79.72%-49.30%11/5/2025 (Estimated)Latest NLTX, GYRE, TNGX, and NRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025GYREGyre Therapeutics$0.03$0.02-$0.01$0.04$30.80 million$26.77 million8/5/2025Q2 2025TNGXTango Therapeutics-$0.35-$0.35N/A-$0.35$6.41 million$3.18 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A5.404.87NLTXNeoleukin TherapeuticsN/A15.3315.33NRIXNurix TherapeuticsN/A6.826.82TNGXTango TherapeuticsN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%NLTXNeoleukin Therapeutics52.37%NRIXNurix TherapeuticsN/ATNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics10.00%NLTXNeoleukin Therapeutics1.58%NRIXNurix Therapeutics7.40%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4096.31 million86.68 millionNo DataNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataNRIXNurix Therapeutics30076.45 million70.79 millionOptionableTNGXTango Therapeutics90111.26 million102.92 millionOptionableNLTX, GYRE, TNGX, and NRIX HeadlinesRecent News About These CompaniesInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 86,459 Shares of StockSeptember 10 at 6:00 AM | insidertrades.comTango Therapeutics, Inc. $TNGX Stake Cut by American Century Companies Inc.September 9 at 3:15 AM | marketbeat.comNuveen LLC Purchases New Shares in Tango Therapeutics, Inc. $TNGXSeptember 8 at 3:12 AM | marketbeat.comWalleye Capital LLC Sells 75,255 Shares of Tango Therapeutics, Inc. $TNGXSeptember 6, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 49,116 Shares of Tango Therapeutics, Inc. $TNGXSeptember 6, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Down 5.1% - Time to Sell?September 5, 2025 | marketbeat.comADAR1 Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. $TNGXSeptember 5, 2025 | marketbeat.comNantahala Capital Management LLC Acquires 183,573 Shares of Tango Therapeutics, Inc. $TNGXSeptember 3, 2025 | marketbeat.comSiren L.L.C. Sells 38,555 Shares of Tango Therapeutics, Inc. $TNGXAugust 31, 2025 | marketbeat.comAlgert Global LLC Cuts Position in Tango Therapeutics, Inc. $TNGXAugust 28, 2025 | marketbeat.comRock Ventures Iv L.P. Third Sells 302,194 Shares of Tango Therapeutics (NASDAQ:TNGX) StockAugust 27, 2025 | insidertrades.comTango Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceAugust 26, 2025 | globenewswire.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells $7,711,000.00 in StockAugust 22, 2025 | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by BrokeragesAugust 20, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Tango Therapeutics (TNGX) with Overweight RecommendationAugust 19, 2025 | msn.comTango Therapeutics initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comPiper starts Tango Therapeutics with an Overweight on TNG462 potentialAugust 19, 2025 | msn.comB. Riley Raises Earnings Estimates for Tango TherapeuticsAugust 14, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by XTX Topco LtdAugust 14, 2025 | marketbeat.comTango (TNGX) Q2 Revenue Drops 52%August 5, 2025 | fool.comTango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue EstimatesAugust 5, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLTX, GYRE, TNGX, and NRIX Company DescriptionsGyre Therapeutics NASDAQ:GYRE$8.17 +0.50 (+6.52%) Closing price 04:00 PM EasternExtended Trading$7.92 -0.26 (-3.12%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Neoleukin Therapeutics NASDAQ:NLTX$19.25 -0.20 (-1.03%) As of 09/9/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Nurix Therapeutics NASDAQ:NRIX$8.95 -0.25 (-2.72%) Closing price 04:00 PM EasternExtended Trading$9.01 +0.06 (+0.67%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Tango Therapeutics NASDAQ:TNGX$6.36 -0.46 (-6.74%) Closing price 04:00 PM EasternExtended Trading$6.39 +0.03 (+0.41%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
